Seven of the eighteen cell lines demonstrated very strong retention of radioactivity when incubated with MA5 (Modified Adjuvant radioactive peptide) with five of these being colon adenocarcinoma cell lines (Caco-2, HCT15, HCT116, LoVo, HT29), one being an esophageal adenocarcinoma cell line (SEG1), and one being a Barrett's esophagus cell line (QHTRT).
We have also highlighted the need for improvement in knowledge translation about adjuvant radioactive iodine to individuals being offered this treatment.
We explored the recollections of thyroid cancer survivors on the diagnosis of WDTC, adjuvant radioactive iodine (RAI) treatment, and decision-making related to RAI treatment.
We are currently in the process of developing a computerized decision aid for counselling individuals with early stage papillary thyroid carcinoma on the options of accepting or declining adjuvant radioactive iodine treatment.
Our objective was to explore, from the perspective of thyroid cancer survivors, the experience of a diagnosis of thyroid carcinoma, counseling and decision-making related to adjuvant radioactive iodine treatment, and any short- or long-term consequences of such treatment.
In this survey, strong physician support for the use of adjuvant radioactive treatment in early stage thyroid carcinoma was related to beliefs that this intervention: 1) decreases disease-related mortality and recurrence, and 2) facilitates disease follow-up at low risk of adverse effects [24].
There are no long-term randomized controlled trials examining the efficacy of RAI remnant ablation in thyroid cancer and there are conflicting reports in observational studies on the benefits of adjuvant radioactive in reducing the risk of thyroid cancer-related mortality and recurrence in early stage disease [20] [22].
Various bodies have provided clinical practice guidelines on management of thyroid cancer, with recommendations for adjuvant radioactive iodine treatment in early stage papillary cancer ranging from no radioactive iodine for very early stage disease (such as unifocal tumors <1 cm in diameter) to dose activities of 29.9 mCi to100 mCi [12] [18].
It is not known if a history of RAI treatment has any impact on future long-term quality of life of WDTC survivors nor how the current controversy about the utility of adjuvant radioactive iodine in early stage WDTC impacts patients' perceptions about RAI treatment decision-making.
Total thyroidectomy was performed in 55.1% cases and 34.8% had adjuvant radioactive iodine (RAI).
We recently developed and tested a patient-directed computerized (internet-based) P-DA, explaining the choice of adjuvant radioactive iodine (RAI) or no RAI, for early stage papillary thyroid cancer [ 9– 13].
